表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）的问世开启了 EGFR 突变非小细胞肺癌（NSCLC）的精准治疗时代，特别是三代 EGFR-TKI 奥希替尼，凭借着显著的全身和颅内疗效获益，已成为此类患者的一线标准治疗方案[1-3]。然而，EGFR-TKI 单药治疗存在一定的局限性，比如存在 EGFR L858R ...

表皮生长因子受体（EGFR）突变非小细胞肺癌（NSCLC）具有高度异质性，EGFR 突变类型、共突变状态、肿瘤负荷等均可能影响其靶向治疗效果。FLAURA2 研究最终总生存期（OS）数据显示，一线奥希替尼联合化疗可显著延长 EGFR 突变晚期 ...

"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...

Association between patient tumour characteristics and five-year survival in Nigerian patients with breast cancer.

The FINANCIAL — Insights from experts working on-the-ground in lung cancer, compiled by Boehringer Ingelheim, shed light on challenges faced by patients with advanced stage adenocarcinoma, a type of ...

Analysis utilizing GuardantINFORM™ real-world evidence platform shows cumulative incidence of EGFR C797X mutation was 12.5 percent in NSCLC patients likely to progress after first-line osimertinib ...

AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC EGFR ...

First results of the prospective Neoadjuvant Breast Registry Symphony Trial (NBRST). This is an ASCO Meeting Abstract from the 2013 ASCO Annual Meeting I. This abstract does not include a full text ...

Review of NICE Diagnostics Guidance No. DG9; EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer: review decision Decision to move the existing guidance ...

"The real-time PCR using plasma or body fluids could be a suitable first test for the detection of EGFR mutations." –Lee et al., Asia-Pacific Journal of Clinical Oncology, 2022 To this end, Kyunghoon ...